NeoPhore Limited
- Biotech or pharma, therapeutic R&D
NeoPhore is developing a small molecule DNA mismatch repair inhibitor, which can functionally reproduce the highly immunogenic mismatch repair deficient (MMR-d) genotype in human tumor cell lines, representing an exciting breakthrough with the potential to improve clinical outcomes in large solid tumor patient populations. We expect to have an IND/CTA filed by the end of 2026.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}